DNA Vaccines and Immunity to Herpes Simplex Virus
- 101 Downloads
Infections by herpes simplex virus (HSV) represent an expensive public health problem. Although only rarely a cause of mortality, HSV infections usually cause painful and often distressing lesions and are particularly troublesome since symptomatic recurrent disease is a common outcome once an individual has been infected. Recurrent lesions on the face and genitalia are the most common expression but in some locations, such as the eye, distressing results such as blindness can occur. As regards HSV infections, in 1985 the Committee on Issues and Priorities for New Vaccine Development of the Institute of Medicine set the following goals: a 50% reduction in symptomatic primary infection, a 75% reduction in the number of recurrences and a 60% reduction in the severity of episodes.
KeywordsHerpes Simplex Virus Type Herpes Simplex Virus Infection Intramuscular Immunization High Dose Challenge Herpes Simplex Virus Vaccine
Unable to display preview. Download preview PDF.
- Kriesel JD, Spruance SL, Daynes RA, Araneo B (1996) Nucleic acid vaccine encoding glycoprotein D2 protects mice from herpes simplex virus type 2 disease. J Infect Dis, In pressGoogle Scholar
- Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clones. J Immunol 136:2348–2357Google Scholar
- Nair S, Rouse RJD, Bruce BD, Rouse BT (1996) Interaction between macrophages and dendritic cells involves a putative peptide chaperon. SubmittedGoogle Scholar
- Simmons A, Nash AA (1984) Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent diseases. J Virol 53:128–136Google Scholar
- Stanberry LR (1996) Herpes immunization - on the threshold. J Eueop Acad Dermatol Venerol 7:120–128Google Scholar